Literature DB >> 455584

Vindesine as a single agent in the treatment of advanced malignant melanoma.

S Retsas, K A Newton, G Westbury.   

Abstract

The antitumour effect of vindesine (desacetyl vinvlastine amide sulfate) in disseminated malignant melanoma has been investigated in our oncology service in a phase-II study. Of 25 patients exposed to the drug, 23 were evaluable, and seven of these (30%) were considered objective responders. The observed response of malignant effusions is of particular interest. Side effects related to vindesine are similar to those of the other vinca alkaloids, although alopecia may be more pronounced with the doses used in this study.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 455584     DOI： 10.1007/bf00257190

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  5 in total

Review 1.  Integration of chemotherapy into combined modality therapy of solid tumors. IV. Malignant melanoma.

Authors:  R L Comis; S K Carter
Journal:  Cancer Treat Rev       Date:  1974-12       Impact factor: 12.111

Review 2.  Phase I anti-cancer agents: vindesine (desacetyl vinblastine amide sulfate).

Authors:  R W Dyke; R L Nelson
Journal:  Cancer Treat Rev       Date:  1977-06       Impact factor: 12.111

3.  Combination chemotherapy for disseminated malignant melanoma with DTIC, vincristine, and methyl-CCNU.

Authors:  L H Einhorn; B Furnas
Journal:  Cancer Treat Rep       Date:  1977-08

4.  Combination chemotherapy with bis chloroethyl nitrosourea (BCNU), vincristine and dimethyl triazeno imidazole carboxamide (DTIC) in disseminated malignant melanoma.

Authors:  E M McKelvey; J K Luce; R W Talley; E M Hersh; J S Hewlett; T E Moon
Journal:  Cancer       Date:  1977-01       Impact factor: 6.860

5.  Results with methyl-CCNU and DTIC in metastatic melanoma.

Authors:  M E Costanza; L Nathanson; D Schoenfeld; J Wolter; J Colsky; W Regelson; T Cunningham; N Sedransk
Journal:  Cancer       Date:  1977-09       Impact factor: 6.860
  5 in total
  6 in total

1.  [Combination chemotherapy with cis-dichloro-diammineplatinum (II) and ifosfamide in malignant melanomas (author's transl)].

Authors:  B R Balda; U Jehn; W Klövekorn; A Wohlrab
Journal:  Klin Wochenschr       Date:  1981-07-15

2.  Establishment of Vincristine-resistant and vindesine-resistant lines of murine lymphoblasts in vitro and characterisation of their patterns of cross-resistance and drug sensitivities.

Authors:  B T Hill; R D Whelan
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

3.  Dacarbazine versus dacarbazine-vindesine in disseminated malignant melanoma: a randomized phase II study.

Authors:  U Ringborg; C M Rudenstam; J Hansson; L Hafström; B Stenstam; H Strander
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

4.  Vindesine in advanced breast cancer, lymphoma and melanoma. A Colorado Clinical Oncology Group study.

Authors:  N J DiBella; R Berris; D Garfield; K Fink; J Speer; A Sakamoto
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

Review 5.  [Therapy of malignant melanoma at the stage of distant metastasis].

Authors:  C Garbe; T K Eigentler
Journal:  Hautarzt       Date:  2004-02       Impact factor: 0.751

6.  Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit.

Authors:  S Lakhani; P Selby; J M Bliss; T J Perren; M E Gore; T J McElwain
Journal:  Br J Cancer       Date:  1990-02       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.